[BREAKING] Hemerion obtains the FDA clearance for its next US clinical trial


Hemerion team has been developing its technology since 2010 within the frame of scientific and clinical research teams located in Lille. Our endeavours led to a successful clinical validation in 2021.

July 2023

The U.S. FDA authorizes Hemerion’s IND application for its Pentalafen® / Heliance® product combination

Hemerion addresses upfront management of newly diagnosed glioblastoma, during surgery, before any adjuvant treatment
The FDA authorization enables Hemerion to commence a Phase 1/2 clinical study at University of Pittsburgh Medical Center by Q4 2023 to evaluate the upgraded Pentalafen® / Heliance® platform.
Read the press release
April 2022

Hemerion raises €3.55 million to accelerate the implementation of international clinical trials for the treatment of glioblastoma

Fund raising

One year after the first round of funding, Hemerion’s new €3.55 million financing will accelerate the implementation of international clinical trials for the treatment of glioblastoma.

Read morePress release

April 2022

Mission in Boston: Hemerion prepares its development in the United States

Introducing Hemerion in Boston

Hemerion has set new milestones for its international development during a 5-day mission in Boston.

Read more

October 2021

Hemerion awarded the Galien MedStartup Prize

Galien Prize MedStartup

Hemerion and Mount Sinai Health System (NYC) are collaborating to launch an ambitious clinical trial in 2022. This project has won the “Best Collaboration in the MedTech and Digital Health” award of the Galien Medstartup Prize: an international recognition that perfectly kickstarts the Hemerion development in the USA.

Read morePress release

September 2021

Phase II study granted authorization in Europe

Authorization granted for a phase 2 clinical trial that aims to evaluate the technology developed by Hemerion. This study is sponsored by the Lille University Hopital (France).

CHU Lille Logo

June 2021

Preliminary results published in Journal of Neuro-Oncology

Ground breaking preliminary results from the clinical study are published in the Journal of Neuro-Oncology. The Hemerion’s technology covered the 2018’s May issue.

Read more


January 2021

FDA grants Hemerion Orphan Drug designation

In the USA, the Hemerion’s technology becomes granted Orphan Drug Designation by the FDA.

January 2021

Hemerion gathers 1.5M€ in funding

Hemerion Technology
For its preliminary funding round, Hemerion gathers 1.5M€ in dilutive and non-dilutive funding to further validate its therapeutic approach.
December 2020

Hemerion wins the Réseau Entreprendre® award

Hemerion is one of the 2020 laureates of the Réseau Entreprendre®, the first international private network of business leaders, with 126 locations worldwide, grouped in 65 associations.

Logo Réseau Entreprendre Nord

December 2020

Hemerion wins Hodéfi award

Hemerion is one of the winners designated by Hodéfi, an association that finances and supports innovative companies in the Hauts-de-France region, and has received one of its first grants.

Logo Hodéfi

December 2020

Therapeutic Innovation Prize

Hemerion wins the therapeutic innovation prize awarded by HDFID, an economic development and innovation agency supported by the Hauts de France Region.

Logo Hauts-de-France Innovation

December 2020

Technology transfer

SATT Nord, a specialist in technology transfer from public research laboratories, grants Hemerion Therapeutics an exclusive license to exploit the anti-cancer technology co-developed by INSERM, the University of Lille and the Lille University Hospital.

Partner logos

October 2020

Hemerion joins Neighborhood

Hemerion joins the Voisin Consulting Neighborhood program, a life science innovation center that offers tailored mentoring, coaching and global access to health tech entrepreneurs.Neigborhood logo
September 2020

Establishment of Hemerion Therapeutics


Hemerion Therapeutics is founded by the scientists and inventors of the technology, among them M. Vermandel, C. Dupont, N. Reyns, S. Mordon and M. Andraud gather deep scientific how-know and entrepreneurship skills to lead the company. In the mean time, Hemerion is awarded the French Tech Label that recognizes high potential start-up companies.

Logo La French Tech

July 2020

I-Lab innovation competition

Hemerion is awarded during I-Lab innovation competition and granted to upgrade its lead product and better meet neurosurgeons needs.
December 2019

University of Lille Foundation awards Hemerion Therapeutics

The University of Lille’s Foundation awards the Hemerion Therapeutics founders for their scientific and entrepreuneurship involvement establishing a healthtech company.

Logo Fondation Université de Lille

June 2019

Introduction of the Hemerion technology in the USA

Introduction of the Hemerion technology in the USA

The Hemerion technology is demonstrated by Pr. N. Reyns at an international neurosurgery meeting in Cambridge – Boston (MA, USA) and in New-York (NY, USA) during Fluorescence-Guided Surgery Brain Tumor Symposiums hosted at The Icahn School of Medicine at Mount Sinai by Pr. C. G. Hadjipanayis.

October 2018

European Neurosurgery Congress

European Neurosurgery Congress

The Hemerion drug-device combination product is presented during the plenary session of annual congress of the European Association of the Neurosurgery Societies in Brussels (Be). First usability endpoints successfully collected during the Phase I INDYGO are reported to the European’s neurosurgeons community.

September 2018

Hemerion technology introduced in Nature

The clinical world premiere is highlighted in Nature’s 2018 September issue. An article detailing the clinical trial INDYGO and the technology being developed to treat glioblastomas is published in a special issue of journal (https://www.nature.com/articles/d41586-018-06713-6)

June 2018

Patients enrollment successfully completed

The enrollment phase of the clinical trial INDYGO is successfully completed, after only one year. During this study sponsored by the University Hospital of Lille (France) and with  Pr. N. Reyns as the Principal Investigator, 10 patients included from may 2017 to June 2018 have been treated with the Hemerion’s technology.

March 2018

Entrepreneurship program with Eurasanté

The Hemerion’s founders enter the Eurasanté entrepreneurship program, an incubator dedicated to health start-up companies

Logo Eurasanté

July 2017

Awarded by world’s largest medical laser society

M. Vermandel becomes the first ever non-US resident of being the recipient of the ASLMS research grant (American Society of Lasers in Surgery and Medicine) for his work on drugs and laser technologies combination. ASLMS was founded in 1980 and is the world’s largest professional organization dedicated to the field of medical laser.

May 2017

Kick-off of phase I clinical trial: INDYGO

For the first time, our technology combining a photosensitizing drug and an innovative photonic device is delivered upfront, during the surgery of patients newly diagnosed with glioblastoma. 
Indygo is a Phase I study sponsored by the University Hospital of Lille.
CHU Lille Logo
January 2016

Optimizing laser light delivery

The photonic therapy is further improved with a light power regimen study that leads to better tolerance.

January 2015

New preclinical study confirms therapy effects

Medical imaging

A new study allows to optimize the photonic illumination scheme and enhance the therapy effects.

January 2014

Proof of concept

Proof of concept

A first preclinical study proves the effectiveness of Hemerion therapeutics approach on glioblastoma (GBM) human cell lines. The experiments associated a photoactivatable drug and an innovative photonic system.